FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Top 10 questions about breast cancer answered

2.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

3.

Even a few mutated cells can significantly impact how blood cancers develop, study finds

4.

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

5.

Year in Review: Non-Small Cell Lung Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot